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Oral administration of the aromatic retinoid etretinate 
is effective therapy for psoriasis and other epidermal 
hyperproliferative disorders. Since polyamine metabo-
lism is known to be important in cell growth and differ-
entiation, we measured urinary levels of the polyamines 
putrescine, spermidine, and spermine as a reflection of 
cutaneous polyamine metabolism in 19 psoriatic patients 
treated with e tretinate for 16 weeks. Using thin-layer 
chromatography, polyamine determinations were p er-
formed on urine collected pretherapy, during therapy, 
and 8 weeks after therapy was concluded. Good to ex-
cellent clearing of psoriasis occurred in 18 of 19 patients. 
All urinary polyamines showed a downward trend in the 
first week of therapy, prior to s ignificant clinical im-
provement. At week 16 of therapy, the greatest reduction 
in mean urinary polyamine content occurred. Mean pu-
trescine levels decreased from pretherapy to week 16 by 
27 % (p < 0.001), mean spermidine values fell by 34% (p 
< 0.001), and mean spermine levels declined by 37% (p 
= 0.005). These data are consistent with the hypothesis 
that etretinate inhibits polyamine biosynthesis. 
It is now well established tha t oral administration of the 
aromatic retinoid etretinate (Ro 10-9359) is a n effective pso-
riasis th erapy, either alone or in combinat ion with oth er agents 
[1-3]. The m echanism of action of retinoids has not been 
establis hed; however, attention h as fo cused on polyamines a nd 
their possible role in the pathogenesis of psoriasis. Polyamine 
levels are increased in t he involved and uninvolved skin a nd in 
the urine of psoriasis patients [ 4,5] ; furthermore, Proctor et a l 
[6] a nd others [ 4,5], have demonstrated a decrease in both 
urina1·y and skin polya mine levels with effective treatment. 
Whethe r declines in polyamine values r epresent treatment-
induced events or are secondary to lesional resolution produced 
by a n effective therapy is uncl ear. 
Certa in evidence s uggests that polyamines may play a n im-
portant role in the regulation of proliferation. The activity of 
ornithine decarboxylase (ODC), th e rate-limiting enzym e in 
polyamine syn thesis [7], rises prior to the increase in cellular 
prolifera t ion caused by various stimuli both in vitro [8] a nd in 
vivo [9,10). Polyamines added to cell culture systems stimulate 
cell growth [11], while inhibition of polyamine syn thesis by 
treatment with ODC inhibitors impedes cellular proliferat ion 
in vitro [13,14] and in the skin (15]. It has also been shown tha t 
retinoid therapy lowers cutaneous polyamine levels in psoriasis 
patients [16]. As a noninvasive procedure, we wondered 
whether measurement of urinary polyamine levels would refl ect 
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those changes known to occur in th e skin. Therefore, in 19 
patients with severe psoriasis treated with etretinate, we deter-
mined urinary polyamine values for putrescine, spermjdine, and 
spermine before and during t herapy and after th erapy had been 
stopped. 
MATERIALS AND METHODS 
Patients 
Nineteen patients aged 21 to 70 years were selected for study. There 
were 16 men and 3 women. Patients had greater than 20% of their body 
surface area involved with psoriasis or had disabling psoriasis (e.g., 
palmoplantar psoriasis). Psoriasis types included plaque (n = 10). 
erythrodermic (3) , pustular (2), inverse (2) and palmoplantar (2). Ini tial 
treatment consisted of either etretinate or placebo in a random double-
blind design. After 8 weeks, the code was broken and those patients on 
placebo were begun on active drug, while those patients taking etretin-
ate continued to do so. All patients were treated with 1.0 mg/ kg/ day 
for 1 week and 0.5 mg/ kg/ day the second week. Thereafter, dosage was 
adjusted to mainta in maximum clinical response while keeping side 
effects to a degree to lerated by the patient. Etretinate treatment 
continued for a total of 16 weeks in aU patients. Subsequently subjects 
were followed for 8 weeks after therapy had been stopped. Pat1ents 
avoided sunlight and used only bland emollients as adjunctive therapy. 
Polya.min.es 
Refrigerated 24-hr collections of urine in amber jugs containing 10 
ml of 12 M HCl were obtained from patients pretherapy, at weeks 1, 2, 
4, 8, 12, and 16 during therapy, and weeks 4 and 8 afte r treatment had 
been stopped. After thorough mixing, 15-ml aliquots were removed for 
analysis and stored at - 70°C. 
Analysis of Polyamin.es 
Urine samples with added tri tiated polyamines as tracers were hy-
ru-olyzed in 6 M HCl, evaporated to dryness, and resuspended in 1% 
perchloric acid. The polyamines were partially purified by Dowex 50 
chromatography [17]. The column fractions containing the polyamines 
were evaporated to ru·yness and resuspended in water. The polyamines 
were dansylated by the method of Seiler and Wiechmann [18] with 
modifications [19). The dansylated amines were separated by two-
dimensional thin-layer chromatography [20]. The separated com-
pounds were visualized with an ultraviolet light (wavelength 365 nm), 
scraped from the plates, and resuspended in benzene. The concentra-
tion of the polyamine derivatives was determined flu orometrica lly. 
Recoveries were determined by quantitating the amount of tracer in 
the benzene fractions. 
Statistical Analysis 
Statistical analysis was performed using pairwise comparisons follow-
ing repeated measures analysis of variance and Student's t-test. 
RESULTS 
Clinical Response 
Eighteen of 19 patients taking etretinate had good to excellen t 
clearing of psoriasis during the 16-week trial. One pat ient with 
plaque-type psoriasis failed to respond satisfactorily. Typical 
cu taneous side effects of cheilit is, peeling of the skin of palms 
a nd soles, and hair loss were seen, but no patient discontinued 
etretinate as a result. 
Nine patie nts received a n 8-week placebo period, during 
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FIG 1. Mea n urinar y polyamine levels 
a nd mean clin ica l response during the 
study in 19 patients with psoriasis. The 
mean etretinate dose is indicated by the 
shaded area. The vertica l line at week 
8/0 indicates the conclusion of the 8-
week place bo period (n = 9), and t he 
beginning of etretinate therapy for a ll 
patients. The vertical line at week 16 
indicates the conclusion of etretinate 
t herapy; patients were monitored for an 
additional 8 weeks. Compared to week 0, 
mean polyamine levels for the 19 pa-
tients were significantly decreased dur-
ing etretinate t hera py: at week 1 for sper-
midine, p < 0.05; at week 16 for putres-
cine, p < 0.001, spermidine, p < 0.001, 
and spermine, p 0.005. Key: 
e e a ll pa tients; •- -- -• pa-
tients administered placebo for 8 weeks 
preceding etretinate therapy (n = 9) ; 
e. · · · e patients receiving only etretin-
ate (n = 10). Hesponse to therapy was 
determined at each lime point by phy-
s ician ratings based on a scale of: 0 = 
excellent; l. = very good, 2 = good, 3 = 
poor, 4 = no response, 5 = worse. 
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which they demonstrated no improvement in their psoriasis. 
Once treatment began with etretinate, their clinical course was 
similar to that of the group which received only etretinate 
therapy (Fig 1) . 
Polyamine Levels 
The mean 24-hr urinary levels of each polyamine decreased 
in the 19 patients during etretinate therapy. Decreases in all 3 
polyamines occurred after 1 week of therapy prior to significant 
clinical response. In the first week, polyamine values declined 
by 21% for putrescine, 30% for spermidine, and 14% for sperm-
ine; however only the change for spermidine was significant ( p 
< 0.05). At week 2, following a 50% decrease in the etretinate 
.. 
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dose, all polyamine levels returned toward pretreatment values. 
After week 2 the dosage was again increased; the subsequent 
mean urinary polyamine level measurements (week 4) were 
decreased (Fig 1, Table I). Thereafter, polyamine levels gradu-
ally decreased throughout the therapy period. The decrease 
from pretherapy to week 16 of therapy was significant for all 3 
polyamines (p :::: 0.005). The levels of all 3 polyamines rose 
after etretinate was discontinued, and 8 weeks after therapy 
had been stopped, mean polyamine values were not statistically 
different from pretherapy. The spermidine to spermine ratio 
did not vary from pretreatment levels throughout the study. 
Nine patients received placebo for an 8-week period prior to 
their 16 weeks of etretinate therapy. Their initial mean polya-
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TABLE I. Mean urine polyamines ±standard deviation " 
Pretherapy 
During therapy 
After therapy 
"nmole/mg crea tin ine (n = 19). 
Time 
Week 0 
Week 1 
Week 2 
Week 4 
Week 16 
Week 24 
" p < 0.05 from pretherapy (week 0). 
' p :::= 0.005 from pretherapy (week 0). 
FIG 2. Urina ry polyamine levels in 1 
patient who fai led to improve during 
etretinate t herapy. The dose of etretinc 
ate is indicated by the shaded area. 
Putrescine 
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mine levels were not statistically different from the fu·st values 
obtained from the group that was randomly assigned etretinate-
only therapy. However, during the placebo period, polyamine 
levels tended to increase (Fig 1). Mea n values for each polya-
mine just prior to etretinate therapy had become significantly 
higher (p < 0.05) in the group receiving placebo than in t he 10 
patients who had only etretinate treatment (Fig 1) , which may 
be the result of 8 weeks of disease activity unbridled by any 
therapeutic measures. After the star t of etretinate therapy, the 
pattern of polyamine changes in the patients who had received 
placebo t reatment was similar to t hat of the group who took 
only retinoid therapy. At the end of 16 weeks of etretinate 
therapy, the difference in mean polyamine levels between the 
placebo and etretinate-only groups was not statistically signifi-
cant. 
In the 1 patient who failed to improve clinically, polyamine 
levels followed the same pattern as that of responders, decreas-
ing during treatment and increasing after t herapy was discon-
tinued (Fig 2). 
DISCUSSION 
The levels of urinary polyamines have been investigated in 
numerous diseases [21]. As a noninvasive procedure with min-
imal patient inconvenience, we felt that monitoring polyamine 
changes in urine would be idea l during t herapy for benign 
hyperplastic conditions such as psoriasis . In this study, we have 
shown that urinary polyamine levels fall during the treatment 
of psorias is with the oral aromatic re tinoid etretinate. 
Evidence consistent with a direct effect of etretinate on 
Spermid ine Spermine 
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polyamine synthesis occurred during the early weeks of therapy. 
At week 1 we showed a downward trend (Fig 1) in a ll 3 urinary 
polyamine levels which preceded the onset of significant clinical 
improvement. Our patients received 1.0 mg/ kg/ day during 
week 1 and were reduced to 0.5 mg/ kg/day during week 2. The 
ini t ia l decrease in polyamine levels at the end of week 1 was 
followed at t he end of week 2 by an increase toward pretreat-
ment levels in the mean values of all 3 polyamines. At the end 
of week 2 the dosage of etretinate was increased to a mean of 
0.92 mg/ kg/day and maintained at that level for the next 2 
weeks. Polyamine levels subsequently fell as measured at week 
4. Thus changes in mean urinary polyamine levels appear to be 
closely tied to the dose of etretinate. This inverse relationship 
between changes in polyamine levels and etretinate dosage may 
have represented a dose-related effect, since apparent inhibi t ion 
of polyamine production by etretinate was lessened when the 
dose was reduced, and then restored when the dose was raised. 
Further support for a direct etretinate effect on polyamine 
synthesis was seen in the patient whose polyamine levels de-
creased despite increased disease activi ty. In this patient, 
changes in polyamine levels clearly were not secondary to 
disease improvement, and therefore we presume that these 
polyamine changes were due solely to etretinate administration 
(Fig 2) . 
Evidence exists that supports the hypothesis that the reti-
noids may exert their beneficial effects on psoriasis by altering 
the levels of polyamines in the skin [15,16,22-24). Lauharanta 
et al [16], using a similaT treatment protocol, achieved anala-
gous results for polyamine levels in the skin of psoriasis patients. 
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In our study, mean urinary levels of putrescine, spermidine, and 
spermine declined by 27%, 34%, and 37%, respectively by week 
16 of t herapy; Lauharanta et al found decreases in skin polya-
mines of 72%, 66%, and 43% at remission. The lesser degrees of 
cha nges seen in our study may retlect "background" contribu-
tion of polyamines from tissues other than skin, which would 
tend to obscure skin-related changes in urina ry polyamine 
levels. Nevertheless, urinary polyamine measurements accu-
rately retlect changes occurring in cutaneous polyamine levels 
and are easier to obtain repeatedly. 
Other investigators employing topical corticosteroids [ 4], 
dithranol [5,6), or specific inhibitors of ODC [25) have demon-
strated decreases of either ODC activity or po lyamine synthesis 
or both in skin and urine in association with improved psoriasis. 
Several investigative groups [15,22- 24) have suggested that the 
t herapeutic efficacy of retinoids in hyperproliferative skin dis-
orders may result from inhibition of ODC. Although we did not 
measure ODC activity per se, we did demonstrate alterations in 
the products of that enzyme, namely polyamine levels, which 
varied with the retinoid dose. Urinary polyamine levels declined 
in our study prior to clinical improvement a nd then remained 
at reduced levels throughout the period of etretinate therapy, 
further supporting the hypothesis that retinoids directly mod-
ulate polyamine synthesis. It is likely that other compounds 
possessing the ability to inhibit the synt hesis of polyamines wil l 
be effective in the treatment of psoriasis. We believe that a 
continued search for and investigat ion of such agents are war-
ranted. 
We thank Lenore Rhodes for technical assistance and Mary Anne 
Jordan for preparing the figures. Hoffmann-LaRoche, Inc., Nutley, 
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